References
- BalzariniJHolyAJindrichJDifferential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurineAntimicrob Agents Chemother1993372 332 3388452366
- FardisMOliyaiRCase study: tenofovir disoproxil fumarate: an oral prodrug of tenofovir ProdrugsNew York, NYSpringer2007 1347 1357
- JenhAMThioCLPhamPATenofovir for the treatment of hepatitis B virusPharmacotherapy20092910 1212 122719792994
- YuanLCDahlTCOliyaiRDegradation kinetics of oxycarbonyloxymethyl prodrugs of phosphonates in solutionPharm Res2001182 234 23711405296
- OzarasRMeteBCeylanBFirst-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatmentEur J Gastroenterol Hepatol2014267 774 78024901822
- Food And Drug Administration Center for Drug Evaluation and ResearchClinical Pharmacology and Biopharmaceutics Review of NDA Number 21–356, VireadRockville, MDUS Food and Drug Admini stration Division of Neuropharmacological Drug Products2001
- Viread® [drug label]Foster City, CAGilead Sciences Inc2012
- MallantsRVan OosterwyckKVan VaeckLMolsRDe ClercqEAugustijnsPMultidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolitesXenobiotica20053510–11 1055 106616393861
- StahlPHWermuthCGHandbook of Pharmaceutical Salts: Properties, Selection, and UseWeinheimWiley VCH2002
- World Medical AssociationWorld Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjectsJAMA201331020 2191 219424141714
- Food And Drug AdministrationGuidance for industry, E6 good clinical practice: consolidated guidancePresented at International Conference on Harmonisation Good Clinical PracticeFederal RegisterRockville, MDU.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER)/Center for Biologics Evaluation and Research (CBER), ICH1996101997 691 709
- Korea Ministry of Food and Drug SafetyGuidance document for bioequivalence studies updated in 20122010 Available from: http://drug.mfds.go.kr/html/CLASS/board/download.jsp?boardType=BOARD&boardSeq=104&seq=2731&fileSeq=1966Accessed October 30, 2017 Korean
- Food and Drug Administration Center for Drug Evaluation and ResearchGuidance for industry: bioavailability and bioequivalence studies for orally administered drug products – general considerations2003 Available from: https://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFI-BioAvail-BioEquiv.pdfAccessed October 30, 2017
- ParkSGLimJIKimYJNovel tenofovir disoproxil salt and the preparation method thereof: Google Patents2015 Available from: https://www.google.com/patents/WO2015002434A1?cl=enAccessed October 30, 2017
- YehWWFraserIPCaroLNo Meaningful Pharmacokinetic Interaction between HCV Protease Inhibitor MK-5172 abd Tenofovir or RaltegravirPresented at 2014 Conference on Retroviruses and Opportunistic InfectionsMarch 3–6, 2014Boston
- Kullak-UblickGAStiegerBMeierPJEnterohepatic bile salt transporters in normal physiology and liver diseaseGastroenterology20041261 322 34214699511